Tumor necrosis factor alpha
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.
-
Citations
26 Claims
-
1-16. -16. (canceled)
-
17. An isolated nucleic acid molecule comprising 15 to 500 contiguous nucleotides of SEQ ID NO:
- 1 (tumor necrosis factor alpha) including a nucleotide selected from the group consisting of;
(a) nucleotide 87 of SEQ ID NO;
1 wherein G is replaced by T;
(b) nucleotide 779 of SEQ ID NO;
1 wherein A is replaced by C;
(c) nucleotide 1155 of SEQ ID NO;
1 wherein G is replaced by A; and
(d) nucleotide 1420 of SEQ ID NO;
1 wherein G is replaced by A. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26)
- 1 (tumor necrosis factor alpha) including a nucleotide selected from the group consisting of;
Specification